Merck KGaA
Merck KGaA operates as a science and technology company in Germany and internationally. It operates through Life Science, Healthcare, and Electronics segments. The Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as the industrial sector. This segment offers science and lab solutions comprising reagents, consumables,… Read more
Market Cap & Net Worth: Merck KGaA (MRK)
Merck KGaA (XETRA:MRK) has a market capitalization of $14.35 Billion (€13.98 Billion) as of March 18, 2026. Listed on the XETRA stock exchange, this Germany-based company holds position #1274 globally and #89 in its home market, demonstrating a -1.77% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Merck KGaA's stock price €108.20 by its total outstanding shares 129242251 (129.24 Million).
Merck KGaA Market Cap History: 2015 to 2026
Merck KGaA's market capitalization history from 2015 to 2026. Data shows growth from $10.47 Billion to $14.35 Billion (4.27% CAGR).
Index Memberships
Merck KGaA is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
HDAX Performance
GDAXHI
|
$470.02 Billion | 3.06% | #6 of 99 |
|
HDAX Price
GDAXHIP
|
$472.59 Billion | 3.04% | #6 of 102 |
|
DAX Index
GDAXI
|
$446.13 Billion | 3.22% | #6 of 40 |
|
DAX Price
GDAXIP
|
$446.13 Billion | 3.22% | #6 of 40 |
|
STOXX Europe Large 200 EUR Price
LCXP
|
$1.30 Trillion | 1.11% | #19 of 182 |
|
STOXX Europe Large 200 Net Return
LCXR
|
$1.30 Trillion | 1.11% | #19 of 182 |
Weight: Merck KGaA's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Merck KGaA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Merck KGaA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.88x
Merck KGaA's market cap is 0.88 times its annual revenue
1.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
6.68x
Merck KGaA's market cap is 6.68 times its annual earnings
10.29x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $10.47 Billion | $12.84 Billion | $1.11 Billion | 0.82x | 9.40x |
| 2016 | $11.75 Billion | $15.02 Billion | $1.63 Billion | 0.78x | 7.21x |
| 2017 | $10.75 Billion | $15.33 Billion | $2.60 Billion | 0.70x | 4.13x |
| 2018 | $10.94 Billion | $14.84 Billion | $3.37 Billion | 0.74x | 3.24x |
| 2019 | $12.98 Billion | $16.15 Billion | $1.32 Billion | 0.80x | 9.84x |
| 2020 | $17.73 Billion | $17.53 Billion | $1.99 Billion | 1.01x | 8.92x |
| 2021 | $28.96 Billion | $19.69 Billion | $3.06 Billion | 1.47x | 9.48x |
| 2022 | $23.32 Billion | $22.23 Billion | $3.33 Billion | 1.05x | 7.01x |
| 2023 | $18.84 Billion | $20.99 Billion | $2.82 Billion | 0.90x | 6.67x |
| 2024 | $18.56 Billion | $21.16 Billion | $2.78 Billion | 0.88x | 6.68x |
Competitor Companies of MRK by Market Capitalization
Companies near Merck KGaA in the global market cap rankings as of March 18, 2026.
Key companies related to Merck KGaA by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Merck KGaA Historical Marketcap From 2015 to 2026
Between 2015 and today, Merck KGaA's market cap moved from $10.47 Billion to $ 14.35 Billion, with a yearly change of 4.27%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €14.35 Billion | -11.75% |
| 2025 | €16.26 Billion | -12.37% |
| 2024 | €18.56 Billion | -1.49% |
| 2023 | €18.84 Billion | -19.23% |
| 2022 | €23.32 Billion | -19.46% |
| 2021 | €28.96 Billion | +63.33% |
| 2020 | €17.73 Billion | +36.58% |
| 2019 | €12.98 Billion | +18.63% |
| 2018 | €10.94 Billion | +1.79% |
| 2017 | €10.75 Billion | -8.46% |
| 2016 | €11.75 Billion | +12.13% |
| 2015 | €10.47 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Merck KGaA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $14.35 Billion USD |
| MoneyControl | $14.35 Billion USD |
| MarketWatch | $14.35 Billion USD |
| marketcap.company | $14.35 Billion USD |
| Reuters | $14.35 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.